Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEP-701 in Severe Plaque Psoriasis
NCT00236119Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Jun 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lestaurtinib in plaque psoriasis (4 arms), sponsored by Cephalon, Inc. Primary endpoint: Physicians Static Global Assessment at 87 days. Started Jun 2005; status: completed.
02
Drugs
lestaurtinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00236119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236119.